Skip to main content

Spasticity, Muscle

1
Pipeline Programs
3
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Elpida Therapeutics
1 program
1
MELPIDAPhase 1/21 trial
Active Trials
NCT05518188Recruiting4Est. Oct 2030
Ipsen
IpsenChina - Tianjin
2 programs
Bedside Referral ToolN/A1 trial
Data collectionN/A1 trial
Active Trials
NCT03209960Completed60Est. Aug 2018
NCT03442660Completed104Est. Aug 2019
AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
Neurological ExaminationN/A1 trial
Neurological ExaminationN/A1 trial
Active Trials
NCT03250988Completed60Est. Aug 2018
NCT03211390Completed60Est. Aug 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Elpida TherapeuticsMELPIDA
IpsenData collection
IpsenBedside Referral Tool
AbbVieNeurological Examination
AbbVieNeurological Examination

Clinical Trials (5)

Total enrollment: 288 patients across 5 trials

NCT05518188Elpida TherapeuticsMELPIDA

Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)

Start: Feb 2023Est. completion: Oct 20304 patients
Phase 1/2Recruiting
NCT03442660IpsenData collection

Validation of the Spasticity Related Quality of Life Questionnaire

Start: May 2018Est. completion: Aug 2019104 patients
N/ACompleted
NCT03209960IpsenBedside Referral Tool

Validity and Inter-Rater Reliability of a Novel Bedside Referral Tool for Spasticity

Start: Jan 2018Est. completion: Aug 201860 patients
N/ACompleted
NCT03250988AbbVieNeurological Examination

Prevalence of Comorbid Spasticity and Urinary Incontinence in Residents of a Long-Term Care Facility

Start: Jan 2018Est. completion: Aug 201860 patients
N/ACompleted
NCT03211390AbbVieNeurological Examination

Using Telemedicine to Improve Spasticity Diagnosis Rates

Start: Jan 2018Est. completion: Aug 201860 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 288 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.